I authorize BREC and/or OLOL Children's staff to follow the Asthma Emergency Treatment Plan or administer the medications listed below in the instance of an airway emergency.



Asthma Emergency Treatment Plan

Assess Severity

- Students at high risk for a fatal attack (see Risk Factors for Fatal Asthma Attacks below) require immediate attention after initial treatment.
- Symptoms and signs suggestive of a more serious exacerbation such as marked breathlessness, inability to speak more than short phrases, use of accessory muscles, or drowsiness should result in initial treatment while immediately calling 911.
- Less severe signs and symptoms can be treated initially with assessment of response to therapy and further steps as listed below.

Initial Treatment

- · Inhaled SABA (albuterol) up to two treatments 20 minutes apart of either :
 - · 2-6 puffs by metered-dose inhaler (MDI) and spacer (when available)
 - Nebulizer treatments with albuterol sulfate inhalation solution 0.083% (2.5 mg/3 ml).

Key: SABA: short acting beta2-agonist (quick relief inhaler)

Good Response

No wheezing, cough, or dyspnea (assess tachypnea in young children).

- Contact parent/guardian for follow-up instructions and further management.
- May continue inhaled SABA every 3 to 4 hours for 24-48 hours.
- Return to class and recheck later.

Incomplete Response

Persistent wheezing, cough, and dyspnea (assess tachypnea).

- Continue inhaled SABA as listed under initial treatment above.
- Contact parent/guardian, who should follow up urgently with health care provider.
- If parent/guardian not available, call 911.

Poor Response

Marked wheezing, cough, and dyspnea.

- Repeat inhaled SABA immediately.
- If distress is severe and nonresponsive to initial treatment, call 911, then call parent/guardian.

To Hospital Emergency Department

Modified by Robert Lemanske, MD and Kathleen Shanovich, RN, CPNP from Guidelines for the Diagnosis and Management of Asthma, National Asthma Education and Prevention Program, Expert Panel Report 3, U.S. Department of Health and Human Services, National Institutes of Health, and National Heart, Lung and Blood Institutes of Health, and National Heart, Lung and Blood Institute, October 2007, page 382.

SA³MPRO[™]

© 2022 American Academy of Allergy, Ashma & Immunology, All Rights Reserved.

September 29, 2022

- *Epinephrine Injection 0.15 mg (15-30 kg)
- *Epinephrine Injection 0.3 mg (>30 kg)

Child's Name		
Parent/Guardian	Parent/Guardian	
Print	Signature	Date
